MKC -231 Pharmaceutical Raw Nootropic Powder
Coluracetam MKC 231 Informations de base
| Nom du produit |
Coluracétam |
| Alias |
MKC 231 |
| CAS |
77472-70-9 |
| MF |
C19H23N3O3 |
| MW |
341.4 |
| Pureté |
99.50% |
| Classe |
Qualité pharmaceutique |
| Apparence |
Poudre cristalline blanc cassé. |
| Brand Nmae |
HKYC |
| Standard |
USP |
| Stock |
Mass Stock |
| Packing Methods |
designed disguised packing ways, 100% pass custom guarantee |
| Delivery time |
dans 18 hours after payment confirmed |
| Paiement |
T/T, Western union,Gramme d'argent , Bitcoin |
| Usage |
Coluracetam is mainly applied to promote intellectual product,raw material used in Synthesis |
La description:
Coluracétam (BCI-540) is a nootropic drug of the racetam family.Coluracetam (formerly known as MKC-231) was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer’s disease.
Coluracetam enhances high-affinity choline uptake (ICI) which is the rate-limiting step of acetylcholine (ACh) synthesis, and is the only known choline uptake enhancer to currently exist. Studies have shown
Coluracetam to improve learning impairment on a single oral dose given to rats which have been exposed to cholinergic neurotoxins. Subsequent studies have shown that it may induce long-lasting procognitive effects by changing the choline transporter regulation system.
Applications of Coluracetam/ MKC-231:
Coluracetam is a nootropic drug of the racetam family. Coluracetam was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer’s disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depression disorder (MDD), after being awarded a “Qualifying Therapeutic Discovery Program Grant” by the state of California. Findings from its Phase 2a clinical trials have suggested that it would be an ideal medication for co-morbid MDD with generalized anxiety disorder (GAD). BrainCells Inc is currently out-licensing the drug for this purpose. It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.
Coluracetam enhances high-affinity choline uptake (ICI) which is the rate-limiting step of acetylcholine (ACh) synthesis, and is the only known choline uptake enhancer to currently exist. Studies have shown Coluracetam to improve learning impairment on a single oral dose given to rats which have been exposed to cholinergic neurotoxins. Subsequent studies have shown that it may induce long-lasting procognitive effects by changing the choline transporter regulation system.
Directeur commercial